$0.88
1.20% day before yesterday
Nasdaq, Oct 03, 10:16 pm CET
ISIN
US52886N4060
Symbol
LEXX

Lexaria Bioscience Corp Stock price

$0.88
-0.01 0.92% 1M
-0.65 42.56% 6M
-1.22 58.15% YTD
-2.43 73.45% 1Y
-1.67 65.54% 3Y
-6.62 88.29% 5Y
-3.65 80.59% 10Y
-10.03 91.94% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
-0.01 1.20%
ISIN
US52886N4060
Symbol
LEXX
Industry

Key metrics

Basic
Market capitalization
$19.5m
Enterprise Value
$14.9m
Net debt
positive
Cash
$4.6m
Shares outstanding
19.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
31.5 | 28.6
EV/Sales
24.0 | 21.8
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
90.6%
Return on Equity
-72.1%
ROCE
-217.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$620.0k | $682.4k
EBITDA
$-11.3m | -
EBIT
$-11.4m | $-12.5m
Net Income
$-11.4m | $-12.0m
Free Cash Flow
$-9.9m
Growth (TTM | estimate)
Revenue
63.2% | 48.4%
EBITDA
-142.7% | -
EBIT
-137.8% | -116.8%
Net Income
-134.6% | -106.0%
Free Cash Flow
-102.1%
Margin (TTM | estimate)
Gross
99.6%
EBITDA
-1,837.1% | -
EBIT
-1,851.7%
Net
-1,847.7% | -1,751.4%
Free Cash Flow
-1,600.9%
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
2.5%
Employees
7
Rev per Employee
$70.0k
Show more

Is Lexaria Bioscience Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Lexaria Bioscience Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Lexaria Bioscience Corp forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Lexaria Bioscience Corp forecast:

Buy
88%
Hold
13%

Financial data from Lexaria Bioscience Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
May '25
+/-
%
0.62 0.62
63% 63%
100%
- Direct Costs - -
-
-
0.61 0.61
61% 61%
98%
- Selling and Administrative Expenses 4.69 4.69
51% 51%
756%
- Research and Development Expense 7.32 7.32
287% 287%
1,181%
-11 -11
143% 143%
-1,824%
- Depreciation and Amortization 0.09 0.09
36% 36%
15%
EBIT (Operating Income) EBIT -11 -11
138% 138%
-1,839%
Net Profit -11 -11
135% 135%
-1,835%

In millions USD.

Don't miss a Thing! We will send you all news about Lexaria Bioscience Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexaria Bioscience Corp Stock News

Neutral
Accesswire
5 days ago
KELOWNA, BC / ACCESS Newswire / September 29, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a p...
Neutral
TheNewswire
5 days ago
Kelowna, British Columbia - September 29, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced  at-the-market under Nasdaq rules of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at...
Neutral
TheNewswire
9 days ago
Kelowna, British Columbia – TheNewswire - September 26, 2025 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a purchase price of $1.50 per sha...
More Lexaria Bioscience Corp News

Company Profile

Lexaria Bioscience Corp. is a proprietary drug delivery technology company. Its technology DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a tobacco producer for the development of smokeless, oral-based nicotine products. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Head office United States
CEO Mr. Christopher
Employees 7
Founded 2004
Website www.lexariabioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today